Rosonald Bell, Nicole V. Soucy, Mansi Krishan, and Esra Mutlu Are Elected as 2022–2024 SOT Nominating Committee Members

By Suzanne Fitzpatrick posted 03-24-2022 02:23 PM


SOT is pleased to announce the newly elected members of the SOT Nominating Committee. These members were elected to represent the Membership-At-Large, Regional Chapters, and Specialty Sections, as indicated in this blog.

From the Membership-at-Large
Rosonald Bell, PhD, DABT, ERT, FRSB

Rosonald Bell, PhD, DABT, ERT, FRSB, currently serves as Executive Director, Head of Non-clinical Safety and Development, at Epizyme Inc., developing and overseeing the execution of strategic properties of nonclinical safety as well as managing administrative activities, including budget planning, staffing, and CRO selection. Dr. Bell has more than 29 years of drug development experience in the global biopharmaceutical environment as a board-certified toxicologist, enriched from having the opportunity to work for several major global pharmaceutical companies over his career. Throughout his career, his work has focused on strategic aspects and the design of safety programs to support chemical product development and registration, and the clinical development and licensure for small molecules and biotherapeutics.

Dr. Bell has been an SOT member since 1998 and since this time has served in many leadership positions within the Society, including past membership on the Nominating Committee. He served on the SOT Council for the 2015–2018 term and is a past Councilor of the Toxicologists of African Origin Special Interest Group. In addition to these roles, Dr. Bell also is a Past President and Councilor of the Northeast Regional Chapter, among several additional Component Group memberships.

Of his goals for SOT, Dr. Bell says: “I believe that the Nominating Committee and Society of Toxicology organization as a whole provide a critical platform for scientists and decision-makers to discuss and critique new methods of evidence development, creates new standards of scientific and decision-making excellence, and facilitates transparency in evidence-based decision-making. By continuing its path of excellence and addressing the new challenges of tomorrow through creative programming, education, and service offerings, the Society of Toxicology and its membership will thrive as leaders of scientific creativity, rigor, and integrity and contribute significantly to the health care challenges ahead.”

From the Regional Chapters
Nicole V. Soucy, PhD, DABT

Nicole V. Soucy, PhD, DABT, has worked in the medical device industry since 2006, where she has designed and managed preclinical safety programs to support IDE/PMA submissions for stent- and balloon-based drug delivery programs, led technology development projects to support the biological evaluation of combination medical device products, and led teams of toxicologists and biocompatibility specialists for two major medical device manufacturers, including business with contract pharmaceutical R&D and manufacturing operations. A Diplomate of the American Board of Toxicology since 2012, Dr. Soucy currently serves as a member of the executive committee (Vice President) of the ABT Board of Directors. She also is currently the Director of Global Biocompatibility and Toxicology at Boston Scientific, where she leads a team of 30 scientists supporting new product development and sustaining activities across all business divisions.

Dr. Soucy has been an SOT member since 2000 and is a Past President of the Northland Regional Chapter. She has served as a member of both the Committee on K–12 Education and the Regional Chapter Collaboration and Communication Committee and maintains membership in several Component Groups. In 2005, she was presented with the Board of Publications Award.

Of her goals for SOT, Dr. Soucy says: “My goal for the Society of Toxicology is to promote the career path of the toxicologist to undergraduate and graduate students, despite the dwindling number of dedicated toxicology programs in secondary education. Throughout my career, I have consistently delivered business-critical results with the vision, determination, and skills to develop actionable strategies and tactics for success and have demonstrated excellent collaborative skills to achieve business goals across a highly matrixed environment. I believe these skills will enable my success in helping advance the mission of the Society of Toxicology.”

From the Specialty Sections
Mansi Krishan, PhD, ERT

Dr. Krishan is a Senior Manager, Toxicology, at Becton, Dickinson and Company (BD), where she develops preclinical safety, biocompatibility, chemistry, and toxicological evaluation programs according to the relevant regulatory requirements for various BD medical devices and products. Dr. Krishan is currently a member of the US Pharmacopeia Dietary Supplements Admission, Evaluation & Labeling Expert Committee. She has received awards for her scientific contributions by prestigious toxicology societies, including SOT, EUROTOX, the American College of Toxicology, and the Society of Toxicology, India.

Dr. Krishan has been an active in the Society since joining the membership in 2011. She currently serves as Chair of the Specialty Section Collaboration and Communication Group; Vice President of the Exposure Specialty Section; and Vice President-Elect of the Medical Device and Combination Product Specialty Section. In addition to these roles, Dr. Krishan is the Secretary/Treasurer of the Sustainable Chemicals through Contemporary Toxicology Specialty Section, alongside several additional Component Group memberships.

Of her goals for SOT, Dr. Krishan says: “Starting as a graduate student member and now a full member, SOT has been an integral part of my educational and professional journey. SOT continues to play a significant role in the growth and development of future toxicologists. I am a strong advocate of programs that promote diversity that is not limited to gender, race, ethnicity, or nationality but also includes scientists from different career stages and different sectors, recognizing them for their scientific contributions, and providing them leadership and growth opportunities. My goal for the Nominating Committee is to promote and identify emerging leaders to ensure effective, committed, and diverse leadership to advance the Society’s mission.”

From the Specialty Sections
Esra Mutlu, PhD, DABT

Esra Mutlu, PhD, DABT, is a Chemist at the National Institute of Environmental Health Sciences in the Division of the National Toxicology Program (NTP). In her position, she provides NTP with expertise in organic chemistry, analytical chemistry, and interpretation and application of mass spectrometry and serves on NTP study design teams to provide technical assistance in these areas of chemistry. She manages chemistry contracts conducting toxicokinetic studies and supporting toxicity and carcinogenicity studies of diverse chemicals, including botanicals, PAHs, sunscreen ingredients, and phenolic benzotriazoles. Dr. Mutlu’s research interests include using state-of-the-art mass spectrometric techniques to quantitate products of reactive metabolites of xenobiotics with DNA and other macromolecules. She also is interested in understanding the mode of action of chemicals and their metabolites in vivo.

Dr. Mutlu has been an SOT member since 2008. She recently completed a term as the Secretary/Treasurer of the Mixtures Specialty Section, of which she currently serves as Vice President-Elect.

Of her goals for SOT, Dr. Mutlu says: “The Society of Toxicology has been a great resource and support system throughout my career in toxicology. I strongly believe that the future of toxicology rests in the hands of the new investigators, with guidance of the experts in the field who are actively involved in the SOT community. I especially would like to share my experience with young scientist/new investigators to help showcase their talents and diverse backgrounds to the SOT community.”